로딩 중…
StockDiggingStockDigging

Merck & Co., Inc.

MRK· NYSE
$148.41-0.75%
2026-11-02

Financials

Valuation Metrics

Merck & Co., Inc.'s Market Cap is $366.53B. At end of 2025 it was $262.09B. Ranked #33 of 3,116 in US market (top 1%), #16 of 1,644 on NYSE (top 1.0%), #4 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 2%) by Market Cap.

Investment Metrics(as of 2026-11-02)

MetricValue
Size
Market Cap$366.53B
Revenue$66.40B
Net Income$3.17B
Total Assets$129.80B
Net Assets$41.93B
Employees73,000
Value
P/E115.52x
P/B8.74x
P/S5.52x
EV/EBITDA29.88x
FCF Yield4.38%
Profitability
ROE7.57%
ROA2.44%
Op. Margin16.65%
Revenue Growth4.24%
Earnings Growth-80.66%
Financial Health
Debt Ratio209.42%
Total Debt$53.91B
FCF$16.06B
Cash$6.85B
Current Ratio1.32x
Net Debt/EBITDA3.40x
Dividend
Div. Yield2.26%
Div. Growth5.31%
Performance
1Y Return74.08%
1M Return2.84%
From 52W High-5.43%
1Y MDD-11.90%
Trading
Volume5,590,807 shares
Trading Value$831M
Per Share
EPS$1.28
BPS$16.98

Company Info

CEO Mr. Robert M. Davis J.D.
Employees 73,000
HQ Rahway, United States

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.